MCI-9042
Phase 3Small molecule
Tanabe Pharma CorporationMCI-9042 is one of 49 small molecule programs targeting Cerebral Infarction. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
44 competitors in Cerebral Infarction
#DrugCompanyPhaseTrials
1Plavix
SanofiApproved
Lorelco
SanofiApproved
Prevacid
TakedaApproved
Nimotop
AAzurity Pharmaceuticals
Approved
Gocovri
GGrupo Espanol de Tumores Neuroendocrinos
Approved
Bayer Aspirin
BayerPhase 3
Activase
RochePhase 3
Pletal
OtsukaPhase 3
Xe-133
NNobilis Therapeutics Inc.
Phase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cerebral Infarction1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MCI-9042. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company